FW1256|cas:117089-08-4|西域试剂

FW1256,98.0%

产品编号：Bellancom-121955| CAS NO：117089-08-4| 分子式：C₁₂H₁₀NOPS| 分子量：247.25

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-121955	￥3500.00	杭州北京（现货）
Bellancom-121955	￥6500.00	杭州北京（现货）
Bellancom-121955	￥22500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

FW1256

产品介绍

FW1256 是一种苯基类似物，也是一种缓释硫化氢 (H₂S) 供体。FW1256 抑制 NF-κB 活性，并可诱导细胞凋亡 (apoptosis)，具有有效的抗炎作用，并可用于癌症和心血管疾病的研究。

生物活性

FW1256 is a phenyl analogue and a slow-releasing hydrogen sulfide (H₂S) donor. FW1256 inhibits NF-κB activity and induces cell apoptosis. FW1256 exerts potent anti-inflammatory effects and has the potential for cancer and cardiovascular disease treatment.

体外研究

FW1256 (200 µM; 24.5 hours; AW264.7 cells) treatment significantly reduces IL-1β, COX-2 and iNOS mRNA and protein in LPS-stimulated RAW264.7 macrophages.
FW1256 (200 µM; 24.5 hours; AW264.7 cells) treatment significantly reduces IL-1β, COX-2 and iNOS PROTE and protein in LPS-stimulated RAW264.7 macrophages.
FW1256 concentration dependently decreases TNF-α (IC₅₀ of 61.2 µM), IL-6 (IC₅₀ of 11.7 µM), PGE2 (IC₅₀ of 25.5 µM) and NO (IC₅₀ of 34.6 µM) generation in LPS-stimulated RAW264.7 macrophages and bone marrow-derived macrophages (BMDMs) (IC₅₀s of 414.9 µM, 300.2 µM, 4 µM and 9.5 µM for TNF-α, IL-6, PGE2 and NO, respectively) .
FW1256 decreases NF-κB activation as evidenced by reduced cytosolic phospho-IκBα levels and reduces nuclear p65 levels in LPS-stimulated RAW264.7 macrophages treated with FW1256.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR

Cell Line:	RAW264.7 cells
Concentration:	200 µM
Incubation Time:	24.5 hours
Result:	Significantly reduced IL-1β, COX-2 and iNOS mRNA in LPS-stimulated RAW264.7 macrophages..

Western Blot Analysis

Cell Line:	RAW264.7 cells
Concentration:	200 µM
Incubation Time:	24.5 hours
Result:	Significantly reduced IL-1β, COX-2 and iNOS proteinin LPS-stimulated RAW264.7 macrophages..

体内研究
(In Vivo)

FW1256 (100 mg/kg; intraperitoneal injection; male C57BL/6 mice) treatment reduces IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (20-25 g, 6-10 weeks) injected with E. coli lipopolysaccharide (LPS)
Dosage:	100 mg/kg
Administration:	Intraperitoneal injection
Result:	Reduced IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.

体内研究

FW1256 (100 mg/kg; intraperitoneal injection; male C57BL/6 mice) treatment reduces IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (20-25 g, 6-10 weeks) injected with E. coli lipopolysaccharide (LPS)
Dosage:	100 mg/kg
Administration:	Intraperitoneal injection
Result:	Reduced IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.

体内研究

FW1256 (100 mg/kg; intraperitoneal injection; male C57BL/6 mice) treatment reduces IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57BL/6 mice (20-25 g, 6-10 weeks) injected with E. coli lipopolysaccharide (LPS)
Dosage:	100 mg/kg
Administration:	Intraperitoneal injection
Result:	Reduced IL-1β, TNFα, nitrate/nitrite and PGE2 levels in LPS-treated mice.

性状

Solid

溶解性数据

In Vitro:

DMSO : ≥ 250 mg/mL (1011.12 mM)

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	4.0445 mL	20.2224 mL	40.4449 mL
5 mM	0.8089 mL	4.0445 mL	8.0890 mL
10 mM	0.4044 mL	2.0222 mL	4.0445 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式